News & Events

Experimental Biology 2022

                          Attend the meeting Presentation Information Talk to us at booth 830! Experimental…

Read more
Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia

BEIJING, CHINA, March 8, 2022 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-regional clinical trial…

Read more
Webinar: Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice

Our webinar “Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice” was live on March 16, 2022 at 11AM EDT.…

Read more
Immuno-Oncology 360° 2022 Summit

Attend the meeting Agenda Talk to us at booth 4! IO360˚convenes stakeholders from the science and business communities to report on the latest data impacting…

Read more
Festival of Biologics USA 2022

Speaker: Li Hui M.D., Ph.D., Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Corp Time: 5:10pm PST, March 9th Talk title: Streamlining Therapeutic Antibody Discovery…

Read more
Webinar: Mouse Models to Investigate New Treatments for Inflammatory Disease

We’re pleased to continue our new webinar series informing and updating our network of research professionals. We invite you to join us to learn about…

Read more
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia

Beijing, China, December 9, 2021/PRNewswire/ – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial…

Read more
2021 Highlights: Humanized Model Publications

We are proud to highlight our growing list of publications featuring off-the-shelf and customized mouse, rat, and cancer cell models in well-respected, high-impact journals. Featured below…

Read more
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase I Clinical Trial of YH004 (Anti-4-1BB Monoclonal Antibody) in Australia

BEIJING, CHINA, December 7, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of…

Read more
Biocytogen/Eucure Biopharma’s YH001 (Anti-CTLA-4 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration

BEIJING, November 9, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…

Read more
Back to top